AlloVir, Inc. (NASDAQ:ALVR) Shares Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its stake in AlloVir, Inc. (NASDAQ:ALVR) by 152.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,816 shares of the company’s stock after purchasing an additional 30,072 shares during the period. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ALVR. Marquette Asset Management LLC acquired a new stake in AlloVir in the 1st quarter valued at about $135,000. Acadian Asset Management LLC raised its position in shares of AlloVir by 694.6% during the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after acquiring an additional 1,387,666 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of AlloVir by 127.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after acquiring an additional 54,900 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of AlloVir during the 2nd quarter worth about $55,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Stock Performance

Shares of NASDAQ ALVR opened at $0.80 on Thursday. AlloVir, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $2.49. The firm has a market capitalization of $92.06 million, a PE ratio of -0.48 and a beta of 0.79. The stock’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $0.77.

AlloVir (NASDAQ:ALVR) last issued its earnings results on Wednesday, August 14th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. On average, sell-side analysts forecast that AlloVir, Inc. will post -0.5 earnings per share for the current fiscal year.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.